Tech Transfer Roundup: NCI Licenses Leukemia, Brain Cancer Candidates To Vor, Connectyx
Executive Summary
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
You may also be interested in...
BridgeBio Pharma’s Pipeline Expansion Continues As Existing Portfolio’s Milestones Approach
The company already has more than 20 subsidiaries developing treatments for monogenic diseases and genetically defined cancers, but its deal-making pace has not slowed.
IP Commercializer PureTech Enters CAR-T With Vor BioPharma Start-Up
PureTech Health has moved into the hot area of CAR-T immuno-oncology by launching Vor BioPharma - but the IP commercializer isn't giving details on the start-up's novel chimeric antigen receptor T-cell therapy platform, or how it hopes to remove bottlenecks to the approach's use outside of B-cell cancers.
Reimbursement, Vaccine Issues Dominate EU Group's Korea Concerns
Pharma-related regulatory issues are dominant in the latest annual White Paper from the EU Chamber of Commerce in Korea, accounting for 22 of the 96 concerns raised across 18 industries that will be shared with ministries. Quality of life issues around drugs for chronic disorders, risk-sharing agreements, reimbursement and vaccine policies are some of the key questions raised.